P&FM :: Precision and Future Medicine

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series

Joon Young Hur, Se Hoon Park, Su Jin Lee

Precis Future Med. 2019;3(2):77-84. Published online May 30, 2019
DOI: https://doi.org/10.23838/pfm.2019.00016

Olaratumab and doxorubicin for the treatment of metastatic soft tissue sarcoma: a retrospective case series

Joon Young Hur, Se Hoon Park, Su Jin Lee

Precision and Future Medicine. 2019;3(2):77-84

Link1

Link2 Link3

A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma

Olga Vornicova, Nissim Haim, Gil Bar-Sela

Cancer Chemotherapy and Pharmacology. 2019;84(4):919-923

Link1

Link2 Link3

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

Jana Käthe Striefler, Franziska Brandes, Alexander Baur, Berit Maria Pfitzner, David Kaul, Daniel Rau, Anne Dörr, Maren Schmiester, Georgios Koulaxouzidis, Lars Bullinger, Sven Märdian, Anne Flörcken

BMC Cancer. 2020;20(1):

Link1

Link2 Link3

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

Santiago Zuluaga-Sanchez, Lisa M. Hess, Sorrel E. Wolowacz, Yulia D’yachkova, Emma Hawe, Adrian D. Vickers, James A. Kaye, David Bertwistle

Sarcoma. 2018;2018:1-14

Link1

Link2 Link3

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution

Shoko Marshall, Kenji Nakano, Yoshiya Sugiura, Shinichiro Taira, Makiko Ono, Junichi Tomomatsu, Shunji Takahashi

Sarcoma. 2018;2018:1-7

Link1

Link2 Link3

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma

Alexandra Pender, Robin L Jones

Clinical Pharmacology: Advances and Applications. 2017;Volume 9:159-164

Link1 Link2

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy

Elizabeth J Davis, Rashmi Chugh

Drug Design, Development and Therapy. 2017;Volume 11:3579-3587

Link1 Link2

Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model

Takashi Higuchi, Kentaro Miyake, Norihiko Sugisawa, Hiromichi Oshiro, Zhiying Zhang, Sahar Razmjooei, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M. Hoffman

Cancer Letters. 2019;451:122-127

Link1 Link2

Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal

Irina A. Tikhonova, Tracey Jones-Hughes, James Dunham, Fiona C. Warren, Sophie Robinson, Peter Stephens, Martin Hoyle

PharmacoEconomics. 2018;36(4):507-507

Link1 Link2

Link3

Real-world experience of Olaratumab and Doxorubicin versus Doxorubicin alone for advanced soft-tissue sarcoma in a UK centre

Ian S. Boon, Laura Jaques, Leanne Elder, Margaret Purkis, Jason Wong, Peter Dickinson, Dan Stark, Maria Marples, Rob Turner

Clinical Oncology. 2019;31:e9

Link1 Link2